BeiGene Says BGB-16673 Gets FDA Fast Track Status for Lymphocytic Leukemia, Lymphoma

BeiGene (BGNE) said Monday that BGB-16673, received a fast track designation from the US Food and Drug Administration for potentially treating relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The designation, with support from phase 1/2 safety and efficacy data, is to expedite FDA's review of BGB-16673 as a treatment for adults with CLL or SLL that has relapsed or did not respond to initial treatment, according to BeiGene.

Shares of the company were up 2.8% in recent Monday premarket activity.

Price: 199.23, Change: +5.41, Percent Change: +2.79